Dublin, Feb. 01, 2021 (GLOBE NEWSWIRE) -- The "Coronavirus Disease 2019 (COVID-19) Impact on Novavax Inc." company profile has been added to ResearchAndMarkets.com's offering.
Novavax is a late-stage clinical biotechnology company with a recombinant subunit innovative vaccine platform and an adjuvant platform to develop prophylactic vaccines against infectious diseases.
This report gives an important expert analysis on how COVID-19 will affect Novavax. Findings are based on the industry's most comprehensive platform the Pharma Intelligence Center, including Deals, News, Drugs, Sales, Clinical Trials database and recent analysis.
Reasons to Buy
An overview of how Novavax Inc. will be affected by the COVID-19 pandemic.
Key Topics Covered:
1 Executive Summary
2 Company Overview
3 Regional Analysis
4 Reaction to COVID-19
5 Key Findings
For more information about this company profile visit https://www.researchandmarkets.com/r/isdfgd
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager email@example.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900